Stéphane de Botton (Stephane De Botton, Stéphane De Botton)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 19

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Courtney D D DiNardo, Gail J Roboz, Justin M Watts, Yazan F Madanat, Gabrielle T Prince, Praneeth Baratam, Stéphane de Botton, Anthony S Stein, James M Foran, Martha L Arellano, David A Sallman, Mohammad Hossain, Dylan M Marchione, Xiaofei Bai, Prapti A Patel, Stephanie M Kapsalis, Guillermo Garcia-Manero, Amir T Fathi
Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood advances (2024)
Courtney D D DiNardo, Gail J Roboz, Justin M Watts, Yazan F Madanat, Gabrielle T Prince, Praneeth Baratam, Stéphane de Botton, Anthony S Stein, James M Foran, Martha L Arellano, David A Sallman, Mohammad Hossain, Dylan M Marchione, Xiaofei Bai, Prapti A Patel, Stephanie M Kapsalis, Guillermo Garcia-Manero, Amir T Fathi
Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood advances (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood advances 8 (10) (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood advances 8 (10) (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood advances 8 (10) (2024)
Courtney D D DiNardo, Gail J Roboz, Justin M Watts, Yazan F Madanat, Gabrielle T Prince, Praneeth Baratam, Stéphane de Botton, Anthony Stein, James M Foran, Martha L Arellano, David A Sallman, Mohammad Hossain, Dylan M Marchione, Xiaofei Bai, Prapti A Patel, Stephanie M Kapsalis, Guillermo Garcia-Manero, Amir T Fathi
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood advances 8 (15) (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood advances 8 (10) (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood advances 8 (10) (2024)
Courtney D D DiNardo, Gail J Roboz, Justin M Watts, Yazan F Madanat, Gabrielle T Prince, Praneeth Baratam, Stéphane de Botton, Anthony Stein, James M Foran, Martha L Arellano, David A Sallman, Mohammad Hossain, Dylan M Marchione, Xiaofei Bai, Prapti A Patel, Stephanie M Kapsalis, Guillermo Garcia-Manero, Amir T Fathi
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood advances 8 (15) (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials. Blood advances (2024)
Stéphane de Botton, Pierre Fenaux, Karen W L Yee, Christian Recher, Andrew H Wei, Pau Montesinos, David C Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn S Grove, Brian A Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K Hiwase, Joseph G Jurcic, Jürgen Krauter, Xavier G Thomas, Justin M Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge E Cortes
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood advances (2023)
Christophe Willekens, Claude Chahine, Matteo Dragani, Sabine Khalife-Hachem, Camille Bigenwald, Julien Rossignol, Cristina Castilla-Llorente, Alina Danu, Jean-Marie Michot, Veronique Saada, Sophie Cotteret, Christophe Marzac, Aline Renneville, Isabelle Plo, Sophie Broutin, Nelly Bosselut, Bruno Cassinat, Julien Lazarovici, Nathalie Droin, Stéphane de Botton
When monoclonal gammopathy-associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes. EJHaem 4 (3) (2023)
Loic Vasseur, Laurène Fenwarth, Jérôme Lambert, Stéphane de Botton, Martin Figeac, Céline Villenet, Mael Heiblig, Pierre-Yves Dumas, Christian Récher, Celine Berthon, Emilie Lemasle, Delphine Lebon, Juliette Lambert, Christine Terré, Karine Celli-Lebras, Hervé Dombret, Claude Preudhomme, Meyling H Cheok, Raphaël A Itzykson, Nicolas Duployez
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study. Blood advances (2023)
Courtney D D DiNardo, Stéphane de Botton, Daniel A Pollyea, Richard M Stone, Jessica K Altman, Amir T Fathi, Tharin Limsakun, Min Liang, Sung Choe, Mohammad Hossain, Adriana E Tron, Qian Meng, Stephanie M Kapsalis, Shuchi S Pandya, Eytan M Stein
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study. American journal of hematology (2023)
Stéphane de Botton, Thomas Cluzeau, Carlos Enrique Vigil, Rachel Cook, Philippe Rousselot, David A Rizzieri, Jane L Liesveld, Pierre Fenaux, Thorsten Braun, Anne Banos, Joseph G Jurcic, Mikkael A Sekeres, Michael R Savona, Gail J Roboz, Dale Bixby, Kate Madigan, Angela Volkert, Kristin Stephens, Qing Kang-Fortner, Kristen Baker, Sofia Paul, Michael Robert McKeown, John P Carulli, Matthew Lucas Eaton, Graeme Hodgson, Christopher Fiore, Michael Kelly, David A Roth, Eytan M Stein
Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML. Blood advances (2022)
Stéphane de Botton, Pau Montesinos, Andre Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H Wei, Hans Beier Ommen, Sergey Semochkin, Hee-Je Kim, Richard A Larson, Jamie Koprivnikar, Olga Frankfurt, Felicitas R Thol, Jörg Chromik, Jenny L Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, María-Belén Vidriales, Vadim A Doronin, Hartmut Döhner, Amir T Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martín-Regueira, Courtney D D DiNardo
Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial. Blood (2022)
Stéphane de Botton, Joseph M Brandwein, Andrew H Wei, Arnaud Pigneux, Bruno Quesnel, Xavier Thomas, Ollivier Legrand, Christian Recher, Sylvain Chantepie, Mathilde Hunault-Berger, Nicolas Boissel, Salem A Nehme, Mark G Frattini, Alessandra Tosolini, Roland Marion-Gallois, Jixian J Wang, Chris Cameron, Muhaimen Siddiqui, Brian Hutton, Gary Milkovich, Eytan M Stein
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer medicine 10 (18) (2021)
Matthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, Emmanuel Raffoux, Xavier Thomas, Jean-Pierre Marolleau, Thorsten Braun, Lionel Ades, Sylvain P Chantepie, Emilie Lemasle, Celine Berthon, Jean-Valère Malfuson, Cécile Pautas, Juliette Lambert, Nicolas Boissel, Karine Celli-Lebras, Denis Caillot, Pascal Turlure, Norbert Vey, Arnaud Pigneux, Christian Recher, Christine Terré, Claude Gardin, Raphaël A Itzykson, Claude Preudhomme, Hervé Dombret, Stéphane de Botton
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood 137 (20) (2021)
Amir T Fathi, Eytan M Stein, Courtney D D DiNardo, Mark J Levis, Pau Montesinos, Stéphane de Botton
Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. American journal of hematology 96 (6) (2021)